Lipella Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Lipella Pharmaceuticals's earnings have been declining at an average annual rate of -38.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 10.9% per year.
Key information
-38.2%
Earnings growth rate
-25.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -10.9% |
| Return on equity | -292.2% |
| Net Margin | -881.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Lipella Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -4 | 2 | 0 |
| 30 Jun 24 | 1 | -4 | 2 | 0 |
| 31 Mar 24 | 0 | -5 | 2 | 0 |
| 31 Dec 23 | 0 | -5 | 2 | 0 |
| 30 Sep 23 | 0 | -4 | 2 | 0 |
| 30 Jun 23 | 0 | -4 | 1 | 0 |
| 31 Mar 23 | 0 | -3 | 1 | 0 |
| 31 Dec 22 | 0 | -3 | 0 | 0 |
| 30 Sep 22 | 0 | -3 | 0 | 0 |
| 30 Jun 22 | 0 | -2 | 0 | 0 |
| 31 Mar 22 | 0 | -2 | 0 | 0 |
| 31 Dec 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 1 | 0 | 0 | 0 |
| 31 Dec 19 | 1 | 0 | 0 | 0 |
Quality Earnings: LIPO is currently unprofitable.
Growing Profit Margin: LIPO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LIPO is unprofitable, and losses have increased over the past 5 years at a rate of 38.2% per year.
Accelerating Growth: Unable to compare LIPO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LIPO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: LIPO has a negative Return on Equity (-292.24%), as it is currently unprofitable.